Zosano Pharma Corp (ZSAN) Shares Bought by Telemetry Investments L.L.C.

Telemetry Investments L.L.C. raised its position in shares of Zosano Pharma Corp (NASDAQ:ZSAN) by 37.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 219,040 shares of the biotechnology company’s stock after buying an additional 60,069 shares during the period. Telemetry Investments L.L.C.’s holdings in Zosano Pharma were worth $464,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Exencial Wealth Advisors LLC acquired a new stake in shares of Zosano Pharma during the fourth quarter worth about $34,000. BlackRock Inc. increased its position in shares of Zosano Pharma by 481.7% during the second quarter. BlackRock Inc. now owns 27,549 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 22,813 shares in the last quarter. Northern Trust Corp acquired a new stake in shares of Zosano Pharma during the second quarter worth about $119,000. Dimensional Fund Advisors LP acquired a new stake in shares of Zosano Pharma during the third quarter worth about $121,000. Finally, Nexthera Capital LP increased its position in shares of Zosano Pharma by 47.7% during the third quarter. Nexthera Capital LP now owns 1,033,759 shares of the biotechnology company’s stock worth $4,228,000 after purchasing an additional 333,759 shares in the last quarter. Institutional investors and hedge funds own 46.57% of the company’s stock.

ZSAN traded down $0.13 during trading on Friday, reaching $4.94. The company’s stock had a trading volume of 7,026 shares, compared to its average volume of 2,517,084. Zosano Pharma Corp has a 52-week low of $1.85 and a 52-week high of $21.45.



Zosano Pharma (NASDAQ:ZSAN) last announced its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.85) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.16).

Separately, ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th.

TRADEMARK VIOLATION NOTICE: “Zosano Pharma Corp (ZSAN) Shares Bought by Telemetry Investments L.L.C.” was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://dakotafinancialnews.com/2019/03/15/zosano-pharma-corp-zsan-shares-bought-by-telemetry-investments-l-l-c.html.

Zosano Pharma Company Profile

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.

Further Reading: Understanding Relative Strength Index

Want to see what other hedge funds are holding ZSAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zosano Pharma Corp (NASDAQ:ZSAN).

Institutional Ownership by Quarter for Zosano Pharma (NASDAQ:ZSAN)

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.